DSM-Firmenich completed buyback. DSM-Firmenich stock gains 1.79 percent

Published on 10/09/2026 at 11:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached EUR 4.66 billion in the first half of 2026. DSM-Firmenich stock costs EUR 100.20 on October 9, 2026 after EUR 98.44.

Key points in brief

DSM-Firmenich completed a EUR 540.00 million share repurchase program on October 1, 2026.
The company plans to cancel 6,488,446 shares, reducing issued shares by 2.60 percent.
DSM-Firmenich stock was trading at EUR 100.20 at Lang & Schwarz on October 9, 2026, plus 1.79 percent versus EUR 98.44.

Bauhaus-Poster mit geometrischen Formen, Molekül und Schriftzug SCIENCE — dsm-firmenich AG (ISIN CH1216478797) erscheint als geometrisches Bauhaus-Poster mit Molekülformen und dem Wort SCIENCE, Illustration mit AI erstellt.

DSM-Firmenich (ISIN CH1216478797) was trading at EUR 100.20 at Lang & Schwarz on October 9, 2026 at 11:41 a.m. CEST, up 1.79 percent from the EUR 98.44 prior close. The company had completed its EUR 540.00 million share repurchase program on October 1, 2026, according to dsm-firmenich.

Three buyback milestones define the story

On July 30, 2026, DSM-Firmenich reported EUR 4.66 billion in revenue from continuing operations for the first half of 2026, with 5.00 percent comparable growth and adjusted EBITDA of EUR 900.00 million, according to De Belegger. On September 29, 2026, the company said it had repurchased 313,835 shares for EUR 30.30 million, according to dsm-firmenich. The October 1 completion brought total repurchases to 7,169,147 shares at an average price of EUR 75.32, the company said in its release.

What the buyback changes

DSM-Firmenich intends to cancel 6,488,446 shares by the end of the first quarter of 2027. The reduction would cut issued shares from 253,626,947 to 247,138,501, a decrease of 2.60 percent, according to dsm-firmenich. That lower share count can support per-share measures, but it does not by itself increase operating profit or cash flow.

The latest operating picture combines modest reported growth with a higher underlying rate. First-half comparable revenue growth was 5.00 percent, while comparable growth in the second quarter reached 6.00 percent and adjusted EBITDA was EUR 900.00 million, according to De Belegger. The second-half test is whether that growth converts into cash while the company executes its portfolio changes.

Analyst caution remains part of the valuation debate. BNP Paribas analyst Nicola Tang downgraded DSM-Firmenich from Outperform to Neutral on October 2, 2026, with a EUR 100.00 price target, according to Markets Insider. The target is close to the Lang & Schwarz price, leaving the buyback and cash conversion as more immediate measures of execution.

Next date is capital cancellation

The next dated corporate step is the planned cancellation of 6,488,446 shares by the end of the first quarter of 2027. The company is listed on Euronext Amsterdam and SIX Swiss Exchange, while the Euronext Amsterdam quotation is represented by ticker DSFIR.

Stock trades above prior close

At Lang & Schwarz, DSM-Firmenich stock was trading at EUR 100.20 on October 9, 2026 at 11:41 a.m. CEST, up 1.79 percent versus the EUR 98.44 prior close of October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.